NFKB1 and familial pancreatic carcinoma: Recently, shikonin has been reported to mediate PD-L1 degradation by inhibiting NF-κB/STAT3 and NF-κB/CSN5 signaling pathways and blocking immune evasion in pancreatic cancer [19].